Roche and Genentech Strike Deal With Surmodics For Biodegradable Microparticle Drug Delivery System for Lucentis
October 7, 2009
Submit Comments
Roche and Genentech have signed a licensing agreement with SurModics, Inc., to take advantage of SurModics’ proprietary biodegradable microparticle drug delivery system, to develop and commercialize a sustained delivery formulation for Lucentis in treating age-related macular degeneration. The agreement also provides Roche and Genentech with the opportunity to develop additional compounds using the sustained drug delivery system for the treatment of other ophthalmic diseases.
For the full story, see the SurModics news release.
Also, for more on this, see my new writeup in my online Journal.
Comments
Jump down to form below to submit your own comments
